SLC25A12: for Electron Transport and Aspartate/Glutamate Homeostasis in Mitochondria

Target Name: SLC25A12

NCBI ID: G8604

SLC25A12

SLC25A12: for Electron Transport and Aspartate/Glutamate Homeostasis in Mitochondria

SLC25A12: A Potential Drug Target and Biomarker for Electron Transport and Aspartate/Glutamate Homeostasis in Mitochondria

Mitochondria are critical organelles responsible for generating energy through the process of cellular respiration. They are also responsible for maintaining the cellular environment and participating in various cellular processes. One of the essential proteins involved in these processes is the Electron Transport and Aspartate/Glutamate (ET/ASG) antiporter (SLC25A12), which is a protein that plays a vital role in regulating the transport of essential amino acids, including aspartate and glutamate, into the mitochondria. In this article, we will discuss the potential drug target and biomarker properties of SLC25A12, and its implications for the understanding of electron transport and aspartate/glutamate homeostasis in mitochondria.

Potential Drug Target

SLC25A12 is a member of the family of transmembrane protein (TMP)s, which are involved in the regulation of various cellular processes, including ion and solute transport, as well as signaling pathways. SLC25A12 is primarily localized to the mitochondria, where it plays a crucial role in regulating the transport of essential amino acids, including aspartate and glutamate, into the mitochondria.

SLC25A12 is known to be a protein with high potential as a drug target due to its unique function in regulating the transport of essential amino acids into the mitochondria. The abnormal regulation of aspartate and glutamate transport into the mitochondria can lead to various cellular and physiological disorders, including diseases such as neuromuscular disorders, neurodegenerative diseases, and metabolic disorders. Therefore, targeting SLC25A12 with small molecules or other therapeutic agents has the potential to treat a variety of these disorders.

Biomarker

In addition to its potential drug target properties, SLC25A12 is also a potential biomarker for various diseases associated with misregulated aspartate and glutamate transport into the mitochondria. For example, SLC25A12 has been shown to be altered in various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, which are characterized by the misregulation of aspartate and glutamate transport into the mitochondria.

Furthermore, SLC25A12 has also been shown to be altered in various metabolic disorders, such as obesity, type 2 diabetes, and hypothyroidism, which are characterized by the misregulation of aspartate and glutamate transport into the mitochondria. Therefore, measuring the expression and activity of SLC25A12 could be a useful biomarker for the diagnosis and monitoring of these disorders.

Conclusion

In conclusion, SLC25A12 is a protein that plays a crucial role in regulating the transport of essential amino acids into the mitochondria. Its potential drug target and biomarker properties make it an attractive target for the development of therapeutic agents for various diseases associated with misregulated aspartate and glutamate transport into the mitochondria. Further research is needed to fully understand the role of SLC25A12 in these diseases and to develop effective therapeutic agents.

Protein Name: Solute Carrier Family 25 Member 12

Functions: Mitochondrial electrogenic aspartate/glutamate antiporter that favors efflux of aspartate and entry of glutamate and proton within the mitochondria as part of the malate-aspartate shuttle (PubMed:11566871, PubMed:19641205, PubMed:24515575). Also mediates the uptake of L-cysteinesulfinate by mitochondria in exchange of L-glutamate and proton. Can also exchange L-cysteinesulfinate with aspartate in their anionic form without any proton translocation (PubMed:11566871)

The "SLC25A12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets